(Bloomberg) --Novartis, the Swiss pharma giant, is rethinking its use of office space as a hybrid of at-home and in-office work extends beyond the pandemic.
"We think this is the future," Chief Executive Officer Vas Narasimhan said in an interview with Bloomberg Television. The flexibility should allow Novartis to “access talent pools we would not have been able to access in the past.”
More from MedWatch
In 2015, Genmab partnered with relatively unknown biotech firm Biontech. Reflecting on how far Genmab has come since, CEO Jan van de Winkel is still confident that partnerships, rather than acquisitions, are the way forward. If it had acquired Biontech at the time, the CEO speculates Genmab may have put a stop to other activities – including the Covid-19 vaccine efforts that went on to save millions of lives. This and fairness are worth remembering as biotech firms are increasingly strapped for cash, van de Winkel reflects.